Skip to content
Search

Latest Stories

University of Lincoln tops Guardian's 2024 ranking for pharmacy studies

The University of Lincoln has clinched the top spot on The Guardian's 2024 list for pharmacy and pharmacology studies. This marks a significant advancement from its second-place position in the 2023 rankings, where Ulster University had secured the leading position. Interestingly, Ulster has moved down to claim the second spot this year.

Forty universities were assessed using eight criteria, which encompass student satisfaction with teaching, the effectiveness of feedback from instructors, student-to-staff ratio, expenditure per student (excluding academic staff costs), and the average UCAS scores of entrants under 21.


Also included were the effectiveness of teaching methods, the proportion of students securing graduate-level employment or pursuing further studies within 15 months of graduation, and the percentage of first-year students progressing into their second year.

Among the 40 universities in the ranking list, the University of Lincoln achieved a perfect score of 100 out of 100, followed by Ulster (96.2), Portsmouth (87.9), Leeds (86.3), Glasgow (85.7), Sunderland (84.3), St George’s (84.3), Aberdeen (81.3), UCL (81), and Queen’s, Belfast (80.1).

Westminster secured the 40th position with 33.9 points, while Wolverhampton (35.4), Newcastle (46.6), King’s College London (46.8), Keele (48.2), Manchester (48.8), Kingston (49.9), Birmingham (52.1), Medway School of Pharmacy (52.2), and Hertfordshire (52.9) constituted the group of ten universities with the lowest overall scores.

Ulster performed better than Lincoln in terms of students' satisfaction with teaching and quality of feedback from teachers. However, Lincoln demonstrated strength in the effectiveness of teaching methods, with 98 percent of its graduates entering graduate-level jobs or further study within 15 months of graduation. Ulster's corresponding figure was not provided.

The University of Lincoln provides six courses: MSci Pharmaceutical Science with Business, BSc (Hons) Pharmaceutical Science (with an optional year abroad), MSci Applied Pharmaceutical Science, BSc (Hons) Pharmaceutical Science with Science Foundation Year (including a foundation year and optional year abroad), MPharm Pharmacy, and MPharm Pharmacy with Science Foundation Year. In contrast, Ulster offers one course: MPharm (Hons) Pharmacy.

The 2024 list mentioned universities that provide instruction in pharmacy and pharmacology, including Anglia Ruskin, Bedfordshire, Chester, East London, Edinburgh, Glasgow Caledonian, London Met, Northampton, Southampton, and Suffolk. However, these universities were not assigned a specific ranking.

In August, the Community Pharmacy Workforce Development Group (CPWDG) called on policymakers to address the findings of the 2022 Community Pharmacy Workforce survey for England. The survey unveiled a significant reduction in the workforce, showing a continuous decrease in the number of full-time equivalent pharmacists, pharmacy technicians, and support staff from 2017 to 2022, with no signs of improvement.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less